国药股份
(600511)
| 流通市值：152.83亿 | | | 总市值：208.39亿 |
| 流通股本：5.53亿 | | | 总股本：7.55亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 40,606,422,021.73 | 26,728,336,667.88 | 13,555,320,492.97 | 52,468,280,576.72 |
| 营业收入 | 40,606,422,021.73 | 26,728,336,667.88 | 13,555,320,492.97 | 52,468,280,576.72 |
| 二、营业总成本 | 38,966,530,197.54 | 25,739,069,606.32 | 13,016,129,612.77 | 50,383,129,082.29 |
| 营业成本 | 38,041,023,568.9 | 25,130,710,688.65 | 12,728,593,559.96 | 49,008,442,996.72 |
| 税金及附加 | 112,180,567.63 | 68,108,278.31 | 32,949,483.89 | 137,278,338.03 |
| 销售费用 | 493,159,672.03 | 318,929,726.26 | 144,647,024.71 | 724,522,148.23 |
| 管理费用 | 300,668,224.47 | 205,103,055.64 | 100,051,045.73 | 465,457,096.7 |
| 研发费用 | 34,974,455.66 | 24,767,502.31 | 12,764,925.56 | 69,305,717.06 |
| 财务费用 | -15,476,291.15 | -8,549,644.85 | -2,876,427.08 | -21,877,214.45 |
| 其中:利息费用 | 15,005,579.44 | 10,785,139.64 | 6,111,010 | 27,165,852.32 |
| 其中:利息收入 | 25,984,768.11 | 17,587,628.26 | 8,748,193.71 | 56,090,455.02 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 66,164.34 |
| 加:投资收益 | 424,489,004.97 | 286,926,112.79 | 128,899,404.06 | 566,776,551.25 |
| 资产处置收益 | -126,405.71 | -20,108.4 | -36,112.82 | 212,185.96 |
| 资产减值损失(新) | -44,928,729.01 | -47,378,719.81 | -3,854,838.17 | -5,563,843.29 |
| 信用减值损失(新) | -80,118,661.67 | -61,059,222.23 | -59,194,193.83 | -34,099,335.64 |
| 其他收益 | 5,099,690.33 | 3,098,789.47 | 1,585,472.83 | 9,120,795.19 |
| 四、营业利润 | 1,944,306,723.1 | 1,170,833,913.38 | 606,590,612.27 | 2,621,664,012.24 |
| 加:营业外收入 | 596,901.29 | 365,951.06 | 259,740.53 | 7,022,668.3 |
| 减:营业外支出 | 36,662,978.72 | 28,379,002.44 | 69,278.41 | 28,544,107.2 |
| 五、利润总额 | 1,908,240,645.67 | 1,142,820,862 | 606,781,074.39 | 2,600,142,573.34 |
| 减:所得税费用 | 418,198,544.97 | 268,572,232.46 | 115,266,409.63 | 510,738,987.34 |
| 六、净利润 | 1,490,042,100.7 | 874,248,629.54 | 491,514,664.76 | 2,089,403,586 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,490,042,100.7 | 874,248,629.54 | 491,514,664.76 | 2,089,403,586 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,476,233,652.87 | 879,769,480.08 | 474,263,852.3 | 1,996,593,114.46 |
| 少数股东损益 | 13,808,447.83 | -5,520,850.54 | 17,250,812.46 | 92,810,471.54 |
| 扣除非经常损益后的净利润 | 1,475,460,390.97 | 879,770,348.32 | 465,082,063.18 | 1,970,533,716.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.96 | 1.17 | 0.63 | 2.65 |
| (二)稀释每股收益 | 1.96 | 1.17 | 0.63 | 2.65 |
| 八、其他综合收益 | -9,061,256.31 | -10,608,986.42 | 27,155,628.34 | 23,638,059.9 |
| 归属于母公司股东的其他综合收益 | -9,061,256.31 | -10,608,986.42 | 27,155,628.34 | 23,638,059.9 |
| 九、综合收益总额 | 1,480,980,844.39 | 863,639,643.12 | 518,670,293.1 | 2,113,041,645.9 |
| 归属于母公司股东的综合收益总额 | 1,467,172,396.56 | 869,160,493.66 | 501,419,480.64 | 2,020,231,174.36 |
| 归属于少数股东的综合收益总额 | 13,808,447.83 | -5,520,850.54 | 17,250,812.46 | 92,810,471.54 |
| 公告日期 | 2026-10-21 | 2026-08-20 | 2026-04-23 | 2026-03-20 |
| 审计意见(境内) | | | | 标准无保留意见 |